CryoPort (CYRX) Competitors $7.31 -0.15 (-2.01%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.49 (+6.63%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. EVO, OCUL, SDGR, BHVN, ETNB, ANIP, MESO, EWTX, JANX, and TVTXShould you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Evotec (EVO), Ocular Therapeutix (OCUL), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. CryoPort vs. Its Competitors Evotec Ocular Therapeutix Schrodinger Biohaven 89BIO ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Janux Therapeutics Travere Therapeutics CryoPort (NASDAQ:CYRX) and Evotec (NASDAQ:EVO) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do analysts prefer CYRX or EVO? CryoPort currently has a consensus price target of $11.00, indicating a potential upside of 50.48%. Evotec has a consensus price target of $5.93, indicating a potential upside of 40.60%. Given CryoPort's stronger consensus rating and higher probable upside, equities research analysts plainly believe CryoPort is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do insiders and institutionals believe in CYRX or EVO? 92.9% of CryoPort shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 10.1% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor CYRX or EVO? In the previous week, CryoPort had 7 more articles in the media than Evotec. MarketBeat recorded 9 mentions for CryoPort and 2 mentions for Evotec. Evotec's average media sentiment score of 1.02 beat CryoPort's score of 0.60 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, CYRX or EVO? CryoPort has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoPort$228.38M1.60-$114.76M-$2.34-3.12Evotec$862.40M1.74-$212.18MN/AN/A Which has more volatility & risk, CYRX or EVO? CryoPort has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Is CYRX or EVO more profitable? Evotec has a net margin of -26.34% compared to CryoPort's net margin of -50.15%. CryoPort's return on equity of -11.03% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets CryoPort-50.15% -11.03% -5.54% Evotec -26.34%-21.51%-10.54% SummaryCryoPort beats Evotec on 10 of the 14 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$374.02M$5.87B$7.08B$8.94BDividend YieldN/A2.20%922.94%4.12%P/E Ratio-3.1210.5612.6419.74Price / Sales1.601.22296.48109.12Price / CashN/A10.607.3257.06Price / Book0.982.962.135.37Net Income-$114.76M$189.74M$563.51M$248.34M7 Day Performance0.14%1.55%0.33%1.25%1 Month Performance20.63%1.72%3.99%5.41%1 Year Performance14.40%-2.33%1.20%18.06% CryoPort Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort2.6847 of 5 stars$7.31-2.0%$11.00+50.5%+8.0%$374.02M$228.38M-3.121,186EVOEvotec1.647 of 5 stars$4.20+1.0%$5.93+41.3%-12.5%$1.49B$862.40M0.004,827Positive NewsOCULOcular Therapeutix3.8917 of 5 stars$9.28+0.7%$17.33+86.8%+35.7%$1.48B$59.65M-8.07230SDGRSchrodinger2.5904 of 5 stars$20.12-2.4%$32.80+63.0%+4.0%$1.48B$207.54M-7.65790High Trading VolumeBHVNBiohaven2.7658 of 5 stars$14.11+0.1%$58.46+314.3%-59.3%$1.44BN/A-1.51239ETNB89BIO2.0972 of 5 stars$9.82-0.4%$26.43+169.1%+22.6%$1.43BN/A-2.9140ANIPANI Pharmaceuticals4.237 of 5 stars$65.25-0.4%$80.13+22.8%+2.5%$1.41B$614.38M-51.38600MESOMesoblast2.1315 of 5 stars$10.89-0.3%$18.00+65.3%+59.9%$1.39B$5.67M0.0080News CoverageGap UpEWTXEdgewise Therapeutics3.4567 of 5 stars$13.11-0.5%$40.00+205.1%-27.2%$1.38BN/A-8.4660News CoverageAnalyst ForecastJANXJanux Therapeutics2.2692 of 5 stars$23.10-0.2%$95.25+312.3%-44.9%$1.37B$10.59M-16.9930TVTXTravere Therapeutics3.0395 of 5 stars$14.80+0.2%$32.14+117.2%+80.0%$1.31B$233.18M-5.27460Analyst Forecast Related Companies and Tools Related Companies Evotec Competitors Ocular Therapeutix Competitors Schrodinger Competitors Biohaven Competitors 89BIO Competitors ANI Pharmaceuticals Competitors Mesoblast Competitors Edgewise Therapeutics Competitors Janux Therapeutics Competitors Travere Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
